Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1341
Publisher
MDPI AG
Online
2020-05-25
DOI
10.3390/cancers12051341
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
- (2019) Margaret A. Tempero et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
- (2019) Kevin Lou et al. Science Signaling
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Fibroblast activation protein α-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation
- (2019) Zhang Wen et al. Annals of Translational Medicine
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Gemcitabine and glioblastoma: challenges and current perspectives
- (2018) Chiara Bastiancich et al. DRUG DISCOVERY TODAY
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
- (2018) Sebastian Mueller et al. NATURE
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma
- (2018) Kianna Y. Elahi-Gedwillo et al. CANCER RESEARCH
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Optimizing the outcomes of pancreatic cancer surgery
- (2018) Oliver Strobel et al. Nature Reviews Clinical Oncology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Pancreatic Cancer Chemoresistance to Gemcitabine
- (2017) Manoj Amrutkar et al. Cancers
- KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
- (2017) Jonas Cicenas et al. Cancers
- Ras Conformational Ensembles, Allostery, and Signaling
- (2016) Shaoyong Lu et al. CHEMICAL REVIEWS
- EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients
- (2016) Perrine Créquit et al. LUNG CANCER
- Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer
- (2016) J.-Y. Kim et al. MOLECULAR CANCER RESEARCH
- The role of wild type RAS isoforms in cancer
- (2016) Bingying Zhou et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro
- (2015) Volker Teichgräber et al. Advances in Medical Sciences
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2014) Avnish Kapoor et al. CELL
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
- (2013) Kamal S. Saini et al. CANCER TREATMENT REVIEWS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- (2012) A. B. Turke et al. CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
- (2012) Eric A. Collisson et al. Cancer Discovery
- Analysis of Binding Site Hot Spots on the Surface of Ras GTPase
- (2011) Greg Buhrman et al. JOURNAL OF MOLECULAR BIOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Allosteric Sites on Ras for Lead Generation
- (2011) Barry J. Grant et al. PLoS One
- Challenges of drug resistance in the management of pancreatic cancer
- (2010) Rizwan Sheikh et al. Expert Review of Anticancer Therapy
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now